Millions of people suffering from pre-diabetes may be at a higher risk of stroke, a study published on bmj.com today suggests.
Pre-diabetes is characterised by higher than normal blood glucose levels that, if left untreated, develops into type 2 diabetes. The scale of the problem is enormous and growing, with an estimated 79 million people in the US and 7 million people in the UK affected.
In a critical step that may lead to more effective HIV treatments, Harvard scientists have found pre-existing mutations in a small number of HIV patients. These mutations can cause the virus to develop resistance to the drugs used to slow its progression.
In a critical step that may lead to more effective HIV treatments, Harvard scientists have found that, in a small number of HIV patients, pre-existing mutations in the virus can cause it to develop resistance to the drugs used to slow the progression of the disease.
SAN FRANCISCO – June 7, 2012 – A simple eye test may someday offer an effective way to identify patients who are at high risk for stroke, say researchers at the University of Zurich. They showed that a test called ocular pulse amplitude (OPA) can reliably detect carotid artery stenosis (CAS), a condition that clogs or blocks the arteries that feed the front part of the brain. It's a known risk factor for stroke. The OPA test could be performed by ophthalmologists – physicians who treat eye diseases – during routine exams.
RICHMOND, Va. (June 7, 2012) – A new study from the Virginia Commonwealth University School of Medicine has identified molecular changes responsible for abnormal cholesterol production and metabolism in the livers of patients with a common liver condition, and these changes may explain the severity of a patient's liver disease and risks to their heart health.
(PORTLAND, Ore.) —June 07, 2012—Eleven integrated health systems, with more than 16 million members, have combined de-identified data from their electronic health records to form the largest, most comprehensive private-sector diabetes registry in the nation.
According to a new study published today in the Centers for Disease Control and Prevention's Preventing Chronic Disease, the SUPREME-DM DataLink provides a unique and powerful resource to conduct population-based diabetes research and clinical trials.
Nursing homes that foster an environment in which workers feel they are valued contributors to a team of caregivers provide better care to their residents. That is the conclusion of a study out this month in the journal Health Services Research.
Easy-to-use, inexpensive tests to diagnose infectious diseases are urgently needed in resource-limited countries. A new report based on an American Academy of Microbiology colloquium, "Bringing the Lab to the Patient: Developing Point-of-Care Diagnostics for Resource Limited Settings," describes the challenges inherent in bringing new medical devices and technologies to the areas of the world where they are needed most.
GAITHERSBURG, MD, June 7 – As one of the few probiotics with medical food designation for specific illnesses, VSL#3® has been the subject of a collection of more than 80 studies that have demonstrated its use in the dietary management of IBS, ulcerative colitis, and an ileal pouch. Ulcerative colitis patients, in particular, have been shown to benefit from adding VSL#3 medical food to their prescription drug regimen.
Berlin, Germany, June 7 2012: Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tailoring biologic treatment to individual patients with rheumatoid arthritis (RA) can reduce total costs by €2,595,557 per 272 patients over 3 years (95 percentile range -€2,983,760 to -€2,211,755), whilst increasing effectiveness by an average of 3.67 quality-adjusted life years (QALYs)*. Cost savings were mostly on drug costs.
Berlin, Germany, June 7 2012: Results from a retrospective analysis of contemporary data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, predict, based on estimates from a multivariate regression model, that the cumulative use of anti-tumour necrosis factor drugs (anti-TNFs) for one, two, or three years is associated with reduced risk of cardiovascular events by 24%, 42% and 56% in patients with rheumatoid arthritis (RA) respectively, compared to not using anti-TNF therapies (adjusting for background use of methotrexate or other disease modifyin
Berlin, Germany, June 7 2012: A new American study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, calls for more aggressive management of osteoporosis in the extreme elderly as the true impact of osteoporotic hip fractures in those aged 80 years or older is unveiled.
Berlin, Germany, June 7 2012: A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients treated with certolizumab pegol (CZP) were twice as likely to meet the primary endpoint of ACR20* response at week 12 than those on placebo: 58% on CZP200mg Q2W; and 51.9% on CZP 400 mg Q4W compared to 24.3% on placebo.
Berlin, Germany, June 7 2012: According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with rheumatoid arthritis (RA) who are prescribed biologic treatments have a significantly lower mortality risk (adjusted hazard ratio [HR]: 0.61) than those just treated with traditional disease modifying anti-rheumatic drugs (DMARDs).The study also found the mortality was similar irrespective of the method of action of biologics (anti-tumour necrosis factor drugs [anti-TNFs] or rituximab).
Berlin, Germany, June 7 2012: Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumour necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients treated with traditional disease modifying anti-rheumatic drugs (DMARDs), according to a meta-analysis presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism.